Mutant HER2 needs mutant HER3 to be an effective oncogene

Raphael Trenker; Devan Diwanji; Natalia Jura

doi:10.1016/j.xcrm.2021.100361

Mutant HER2 needs mutant HER3 to be an effective oncogene

Cell Rep Med. 2021 Aug 6;2(8):100361. doi: 10.1016/j.xcrm.2021.100361. eCollection 2021 Aug 17.

Authors

Raphael Trenker¹, Devan Diwanji^{1

2}, Natalia Jura^{1

3}

Affiliations

¹ Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA.
² Medical Scientist Training Program, University of California San Francisco, San Francisco, CA 94158, USA.
³ Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA 94158, USA.

Abstract

Hanker et al. reveal that co-occurring missense mutations in the human epidermal growth factor receptor 2 (HER2) and its catalytically inactive homolog HER3 synergize to promote oncogenic signaling by the HER2/HER3 complex.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Oncogenes / genetics
Phosphorylation
Receptor, ErbB-2* / genetics
Receptor, ErbB-3* / genetics

Substances

ERBB2 protein, human
Receptor, ErbB-2
Receptor, ErbB-3

Abstract

Publication types

MeSH terms

Substances

Grants and funding